Zacks Investment Research
30 Jul 2026, 23:00 UTC · 3d ago
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
30 Jul 2026, 23:00 UTC · 3d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Castle Biosciences reported a quarterly loss of $0.07 per share, significantly beating the Zacks Consensus Estimate of a $0.44 loss. — A substantial earnings surprise of 84.09% typically drives short-term positive price action.
+0.60Castle Biosciences reported quarterly revenues of $103.55 million, surpassing consensus estimates by 18.61%. — Revenue beats combined with earnings beats indicate strong operational performance and growth.
+0.50Castle Biosciences shares have declined approximately 37.1% since the beginning of the year, underperforming the S&P 500. — Significant year-to-date losses suggest a negative trend and lack of investor confidence despite the current beat.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Castle Biosciences currently holds a Zacks Rank #3 (Hold). — A 'Hold' rating indicates a neutral outlook, suggesting the market does not expect immediate aggressive movement.
+0.00Which stocks this story touches
The company reported a significant earnings surprise and revenue beat, though it has underperformed the market year-to-date.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
